Daiichi Sankyo shares results for Ezharmia as lymphoma treatment

December 11, 2023
Medical Communications Daiichi Sankyo, Ezharmia, Oncology, lymphoma

Daiichi Sankyo has announced results from the phase 2 VALENTINE-PTCL01 trial of Ezharmia (valemetostat tosilate), which demonstrated a clinically meaningful …

Regeneron shares data for multiple myeloma treatment

December 8, 2023
Medical Communications Cancer, Oncology, Regeneron, clinical trial

Regeneron Pharmaceuticals has announced positive data from the pivotal LINKER-MM1 trial which assessed linvoseltamab as a treatment for patients with …

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023
Research and Development AI, Acceleration Consortium, Merck, Pharmacy, experimentation

Merck and the Acceleration Consortium have announced their AI-driven experimentation planner Bayesian Back End (BayBE) is now available open-source on …

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023
Business Services AbbVie, Cerevel Therapeutics, Neurology, acquisition

AbbVie and Cerevel Therapeutics have announced an agreement in which AbbVie will acquire Cerevel Therapeutics for $45 per share, or …

ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development

December 7, 2023
Research and Development NAYA Biosciences, NK cell therapies, ONK Therapeutics, Oncology, partnership

ONK Therapeutics and NAYA Biosciences have announced that they have entered into a research partnership to assess combination therapies consisting …

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023
Medical Communications FDA, Fabhalta, Haematology, Novartis, PNH

Novartis has announced that the US Food and Drug Administration has approved Fabhalta (iptacopan) as the first oral monotherapy for …

Teva Pharmaceuticals shares phase 3 data for Ajovy as migraine treatment

December 6, 2023
Research and Development Neurology, Teva Pharmaceuticals, ajovy, obesity

Teva Pharmaceuticals has announced data from a post hoc analysis of two phase 3 clinical studies around the effectiveness of …

British Medical Journal publishes letter calling on government to reduce rate of antidepressant prescribing

December 5, 2023
Medical Communications British Medical Journal, Neurology, antidepressants, over-prescribing

A group of medical professionals and politicians have published an open letter in the British Medical Journal which calls on …

Genentech shares positive results from phase 3 trial for breast cancer treatment

December 5, 2023
Research and Development Genentech, Oncology, breast cancer, oncology

Genentech, a member of the Roche Group, has announced positive results from the phase 3 INAVO120 study, which assessed the …

Dr Stefano Gulià appointed as chief scientific officer of Kling Bio

December 5, 2023
Business Services Kling Bio, Oncology, appointment, chief scientific officer

Kling Bio has announced the appointment of Dr Stefano Gulià as chief scientific officer. Dr Gulià has over 15 years …

Roche to acquire Carmot Therapeutics for $2.7bn

December 4, 2023
Business Services Obesity, Roche, acquisition, diabetes

Roche has announced that it has entered into a definitive merger agreement with Carmot Therapeutics, in which it will acquire …

Eli Lilly’s Jaypirca approved in US for leukaemia and lymphoma treatment

December 4, 2023
Medical Communications Eli Lilly, FDA, Jaypirca, Oncology, leukaemia, lymphoma

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Jaypirca (pirtobrutinib, 100mg and 50mg tablets) …


GSK shares data from global shingles survey

December 1, 2023
Medical Communications GSK, Infections and infestations, data, shingles

GSK has announced data from its new global survey about shingles. The data suggests that there are some significant gaps …

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023
Sales and Marketing AbbVie, Oncology, acquisition

AbbVie and ImmunoGen have announced that AbbVie will acquire ImmunoGen and its lead cancer therapy Elahere (mirvetuximab soratansine-gynx), a first …

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023
Medical Communications FDA, Karuna Therapeutics, NDA, Neurology, schizophrenia

Karuna Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for …

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023
Medical Communications Devices, FDA, Vivos Therapeutics, sleep apnea

Vivos Therapeutics has announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for the …

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023
Research and Development Oncology, Tolremo, clinical trial, drug resistance, solid tumours

Tolremo Therapeutics has announced that it has dosed the first patient in its first-in-human clinical trial to assess the safety, …


FDA grants breakthrough device designation to Inflammatix’s TriVerity Acute Infection and Sepsis Test System

November 29, 2023
Research and Development FDA, Infections and infestations, Inflammatix, TriVerity, infection, sepsis

Inflammatix has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the company’s lead …

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023
Research and Development FDA, Opioid overdose, Pharmacy, opioids, orexo

Orexo has announced that its New Drug Application (NDA) for OX124 has been accepted for review by the US Food …

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023
Research and Development Arcturus Therapeutics, Chronic Diseases, FDA, ODD, cystic fibrosis

Arcturus Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ARCT-032, …

Latest content